Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440833 | 1.00 | SRC (0.41) | SRCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31706943 | 0.87 | PTGDR2 (0.39) | PTGDR2CXCL8NOD1ALDH1A1PKM | |
| SCHEMBL15504622 | 0.86 | SRC (0.43) | SRCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3537397 | 0.85 | PTGDR2 (0.43) | SRCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5004901 | 0.84 | SRC (0.41) | SRCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3538021 | 0.83 | SRC (0.40) | SRCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25324645 | 0.81 | ENPP3 (0.44) | SRCPTGDR2ALDH1A1PKMCYP2C19 | |
| SCHEMBL3717687 | 0.81 | P2RX7 (0.40) | SRCCXCL8NOD1ALDH3A1NOD2 | |
| SCHEMBL25456984 | 0.81 | DCTPP1 (0.40) | SRCPTGDR2CXCL8NOD1ALDH1A1 | |
| SCHEMBL20139600 | 0.79 | HTR1A (0.46) | SRCPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023098699-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098699-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-06-08 | — | — | WO | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3145512-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2011149827-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-7253166-B2 | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| US-20050038049-A1 | Compounds that induce neuronal differentiation in embryonic stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2004093812-A2 | COMPOUNDS THAT INDUCE NEURONAL DIFFERENTIATION IN EMBRYONIC STEM CELLS | IRM LLC (BM) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | BTK, BCL9, LCK | SRC 22/4885PDE4A 4413/4885PDE4B 4417/4885 |
| US-20050038049-A1 | Compounds that induce neuronal differentiation in embryonic stem cells | FER, ERBB3, FLT3 | SRC 67/4885PDE4A 1965/4885PDE4B 1888/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | SRC 22/4885PDE4A 4413/4885PDE4B 4417/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | SRC 207/4885PDE4A 1518/4885PDE4B 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.